Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting

Reuters

2025/06/03

Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603180931) on June 03, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540054779"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540054779\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540054779?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540054779","market":"nz","top_or_hot":-1,"title":"Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603180931) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-03 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603180931) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2KTbxy:1","article_id":"2540054779","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540054779","pubTimestamp":1748952918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Ltd. , a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology  2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.Disclaimer: This news brief was created by Public Technologies  using generative ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KAPA":"Kairos Pharma, Ltd."},"translate_title":"Kairos Pharma在ASCO 2025年年会上公布了癌症免疫治疗药物KROS 101的有希望的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma Unveils Promising Data on Cancer Immunotherapy Drug KROS 101 at ASCO 2025 Annual Meeting\n    \n\n        Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603180931) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}